<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <titles>
      <item>
        <chamberCode />
        <chamberName />
        <parentTitleType />
        <titleType>Short Titles as Introduced</titleType>
        <title>Personal Care Products Safety Act</title>
      </item>
      <item>
        <chamberCode />
        <chamberName />
        <parentTitleType />
        <titleType>Official Title as Introduced</titleType>
        <title>A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics.</title>
      </item>
      <item>
        <chamberCode />
        <chamberName />
        <parentTitleType />
        <titleType>Display Title</titleType>
        <title>Personal Care Products Safety Act</title>
      </item>
    </titles>
    <amendments />
    <congress>114</congress>
    <committeeReports />
    <summaries>
      <billSummaries>
        <item>
          <versionCode>00</versionCode>
          <actionDesc>Introduced in Senate</actionDesc>
          <text><![CDATA[<p><b>Personal Care Products Safety Act</b></p> <p>This bill amends the Federal Food, Drug, and Cosmetic Act to require cosmetics companies to register their facilities with the Food and Drug Administration (FDA) and to submit to the FDA cosmetic ingredient statements that include the amounts of a cosmetic's ingredients. Companies must pay a facility registration fee based on their annual gross sales of cosmetics. The collected fees can only be used for cosmetic safety activities.</p> <p>If the FDA determines that a cosmetic has a reasonable probability of causing serious adverse health consequences, it may prohibit the cosmetic's distribution by suspending the cosmetic ingredient statement. If other cosmetics from the same facility may be affected, the FDA may prohibit distribution from the facility by suspending the facility's registration.</p> <p>The FDA must review the safety of at least five cosmetic ingredients each year, and it may establish conditions for safe use of an ingredient, including a limit on the amount of the ingredient or a requirement for a warning label. A cosmetic cannot be sold if it contains an ingredient that is not safe, not safe under the recommended conditions of use, or not safe in the amount present in the cosmetic. </p> <p>Cosmetics companies are required to report to the FDA any serious adverse health event associated with their cosmetics.</p> <p>The FDA must:</p> <ul> <li>develop and implement cosmetic manufacturing standards that are consistent with existing national and international standards,</li> <li>be allowed to inspect a company's cosmetic safety records,</li> <li>recall a cosmetic that is likely to cause serious adverse health consequences, and</li> <li>encourage cosmetic safety testing practices that minimize the use of animals. </li> </ul>]]></text>
          <lastSummaryUpdateDate>2015-06-01T15:58:52Z</lastSummaryUpdateDate>
          <updateDate>2015-04-20T04:00:00Z</updateDate>
          <actionDate>2015-04-20</actionDate>
          <name>Introduced in Senate</name>
        </item>
      </billSummaries>
    </summaries>
    <createDate>2015-04-21T09:13:10Z</createDate>
    <originChamber>Senate</originChamber>
    <recordedVotes />
    <policyArea>
      <name>Health</name>
    </policyArea>
    <billNumber>1014</billNumber>
    <calendarNumbers />
    <subjects>
      <billSubjects>
        <legislativeSubjects>
          <item>
            <name>Animal protection and human-animal relationships</name>
          </item>
          <item>
            <name>Business records</name>
          </item>
          <item>
            <name>Consumer affairs</name>
          </item>
          <item>
            <name>Drug safety, medical device, and laboratory regulation</name>
          </item>
          <item>
            <name>Government information and archives</name>
          </item>
          <item>
            <name>Licensing and registrations</name>
          </item>
          <item>
            <name>Manufacturing</name>
          </item>
          <item>
            <name>Product safety and quality</name>
          </item>
          <item>
            <name>User charges and fees</name>
          </item>
        </legislativeSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
      </billSubjects>
    </subjects>
    <updateDate>2017-10-27T18:08:57Z</updateDate>
    <sponsors>
      <item>
        <lastName>FEINSTEIN</lastName>
        <bioguideId>F000062</bioguideId>
        <party>D</party>
        <byRequestType />
        <state>CA</state>
        <firstName>DIANNE</firstName>
        <fullName>Sen. Feinstein, Dianne [D-CA]</fullName>
        <identifiers>
          <lisID>1332</lisID>
          <bioguideId>F000062</bioguideId>
          <gpoId>8338</gpoId>
        </identifiers>
        <middleName />
      </item>
    </sponsors>
    <latestAction>
      <actionDate>2016-09-22</actionDate>
      <text>Committee on Health, Education, Labor, and Pensions. Hearings held.</text>
      <links />
    </latestAction>
    <title>Personal Care Products Safety Act</title>
    <laws />
    <cosponsors>
      <item>
        <bioguideId>C001035</bioguideId>
        <party>R</party>
        <fullName>Sen. Collins, Susan M. [R-ME]</fullName>
        <firstName>SUSAN</firstName>
        <middleName>MARGARET</middleName>
        <lastName>COLLINS</lastName>
        <sponsorshipWithdrawnDate />
        <sponsorshipDate>2015-04-20</sponsorshipDate>
        <identifiers>
          <lisID>1541</lisID>
          <bioguideId>C001035</bioguideId>
          <gpoId>8291</gpoId>
        </identifiers>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <state>ME</state>
      </item>
      <item>
        <bioguideId>B000711</bioguideId>
        <party>D</party>
        <fullName>Sen. Boxer, Barbara [D-CA]</fullName>
        <firstName>BARBARA</firstName>
        <middleName />
        <lastName>BOXER</lastName>
        <sponsorshipWithdrawnDate />
        <sponsorshipDate>2015-04-27</sponsorshipDate>
        <identifiers>
          <gpoId>8306</gpoId>
          <lisID>116</lisID>
          <bioguideId>B000711</bioguideId>
        </identifiers>
        <isOriginalCosponsor>False</isOriginalCosponsor>
        <state>CA</state>
      </item>
      <item>
        <bioguideId>K000367</bioguideId>
        <party>D</party>
        <fullName>Sen. Klobuchar, Amy [D-MN]</fullName>
        <firstName>Amy</firstName>
        <middleName />
        <lastName>Klobuchar</lastName>
        <sponsorshipWithdrawnDate />
        <sponsorshipDate>2015-04-30</sponsorshipDate>
        <identifiers>
          <bioguideId>K000367</bioguideId>
          <gpoId>8249</gpoId>
          <lisID>1826</lisID>
        </identifiers>
        <isOriginalCosponsor>False</isOriginalCosponsor>
        <state>MN</state>
      </item>
      <item>
        <bioguideId>K000360</bioguideId>
        <party>R</party>
        <fullName>Sen. Kirk, Mark Steven [R-IL]</fullName>
        <firstName>MARK</firstName>
        <middleName>STEVEN</middleName>
        <lastName>KIRK</lastName>
        <sponsorshipWithdrawnDate />
        <sponsorshipDate>2015-10-01</sponsorshipDate>
        <identifiers>
          <bioguideId>K000360</bioguideId>
          <gpoId>8285</gpoId>
          <lisID>1647</lisID>
        </identifiers>
        <isOriginalCosponsor>False</isOriginalCosponsor>
        <state>IL</state>
      </item>
      <item>
        <bioguideId>H001042</bioguideId>
        <party>D</party>
        <fullName>Sen. Hirono, Mazie K. [D-HI]</fullName>
        <firstName>Mazie</firstName>
        <middleName>K.</middleName>
        <lastName>Hirono</lastName>
        <sponsorshipWithdrawnDate />
        <sponsorshipDate>2015-10-08</sponsorshipDate>
        <identifiers>
          <lisID>1844</lisID>
          <gpoId>7913</gpoId>
          <bioguideId>H001042</bioguideId>
        </identifiers>
        <isOriginalCosponsor>False</isOriginalCosponsor>
        <state>HI</state>
      </item>
      <item>
        <bioguideId>G000555</bioguideId>
        <party>D</party>
        <fullName>Sen. Gillibrand, Kirsten E. [D-NY]</fullName>
        <firstName>Kirsten</firstName>
        <middleName>E.</middleName>
        <lastName>Gillibrand</lastName>
        <sponsorshipWithdrawnDate />
        <sponsorshipDate>2016-03-07</sponsorshipDate>
        <identifiers>
          <lisID>1866</lisID>
          <bioguideId>G000555</bioguideId>
          <gpoId>8336</gpoId>
        </identifiers>
        <isOriginalCosponsor>False</isOriginalCosponsor>
        <state>NY</state>
      </item>
    </cosponsors>
    <actions>
      <actionByCounts>
        <senate>3</senate>
      </actionByCounts>
      <actionTypeCounts>
        <introducedInSenate>1</introducedInSenate>
        <referredToCommittee>1</referredToCommittee>
        <hearingsHeld>1</hearingsHeld>
      </actionTypeCounts>
      <item>
        <actionDate>2016-09-22</actionDate>
        <committee>
          <systemCode>sshr00</systemCode>
          <name>Health, Education, Labor, and Pensions Committee</name>
        </committee>
        <links />
        <sourceSystem>
          <name>Senate</name>
          <code>0</code>
        </sourceSystem>
        <text>Committee on Health, Education, Labor, and Pensions. Hearings held.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2015-04-20</actionDate>
        <committee>
          <systemCode>sshr00</systemCode>
          <name>Health, Education, Labor, and Pensions Committee</name>
        </committee>
        <links>
          <link>
            <name>S2274-2275</name>
            <url>https://www.congress.gov/congressional-record/volume-161/senate-section/page/S2274-2275</url>
          </link>
        </links>
        <sourceSystem>
          <name>Senate</name>
          <code>0</code>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure:CR S2274-2275)</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionCode>10000</actionCode>
        <actionDate>2015-04-20</actionDate>
        <text>Introduced in Senate</text>
        <committee />
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <type>IntroReferral</type>
        <links />
      </item>
    </actions>
    <notes />
    <introducedDate>2015-04-20</introducedDate>
    <billType>S</billType>
    <version>1.0.0</version>
    <committees>
      <billCommittees>
        <item>
          <subcommittees />
          <systemCode>sshr00</systemCode>
          <type>Standing</type>
          <chamber>Senate</chamber>
          <name>Health, Education, Labor, and Pensions Committee</name>
          <activities>
            <item>
              <name>Hearings by</name>
              <date>2016-09-22T14:00:00Z</date>
            </item>
            <item>
              <name>Referred to</name>
              <date>2015-04-20T22:18:28Z</date>
            </item>
          </activities>
        </item>
      </billCommittees>
    </committees>
    <cboCostEstimates />
    <relatedBills />
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

